Felcorekibart vs WIN378

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

Felcorekibart

Developed by GlaxoSmithKline under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Asthmamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07712393 (registry estimate)

No aligned efficacy figure on record for this race.

WIN378

Developed by Windward Bio and partners

Phase 2/3 in Asthmamonoclonal antibody
Weak signal

NCT05790694 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events" (with 6 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2028 · NCT07120503 (registry estimate)

Reported efficacy

Adverse events (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-AUC0-last (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Tmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Cmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-CL/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Vd/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-T1/2 (Strat of Treatment to end of study (approsimately 160days)): In 50 healthy adults given single doses of 20, 60, 200, 600 or 900 mg (eight on drug and two on placebo at each level), treatment-emergent adverse events were comparable between dose groups and placebo, with no trend for increasing risk with dose escalation. Anti-drug antibody incidence was 5% (2 of 40), no injection site reactions occurred, mean half-life ranged from 55.0 to 65.8 days, and exposure increased in a near dose-proportional manner from 20 to 900 mg.

Result source: NCT05790694

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFelcorekibartWIN378
Severe exacerbations, annualised rate—Trial running · NCT07098403—Not reported
Trough FEV1, change—Trial running · NCT07098403—Not reported
ACQ-5, change—Trial running · NCT07098403—Not reported
OCS dose reduction—Trial running · NCT07098403—Not reported

Severe exacerbations, annualised rate

Felcorekibart
—Trial running · NCT07098403
WIN378
—Not reported

Trough FEV1, change

Felcorekibart
—Trial running · NCT07098403
WIN378
—Not reported

ACQ-5, change

Felcorekibart
—Trial running · NCT07098403
WIN378
—Not reported

OCS dose reduction

Felcorekibart
—Trial running · NCT07098403
WIN378
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Felcorekibart: no structured comparison results are available for Asthma.

WIN378: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Felcorekibart's landscape · WIN378's landscape